用于治疗肝脏疾病的聚合物纳米药物。
Polymeric nanomedicines for the treatment of hepatic diseases.
机构信息
Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, 130021, People's Republic of China.
Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, People's Republic of China.
出版信息
J Nanobiotechnology. 2022 Nov 19;20(1):488. doi: 10.1186/s12951-022-01708-y.
The liver is an important organ in the human body and performs many functions, such as digestion, detoxification, metabolism, immune responses, and vitamin and mineral storage. Therefore, disorders of liver functions triggered by various hepatic diseases, including hepatitis B virus infection, nonalcoholic steatohepatitis, hepatic fibrosis, hepatocellular carcinoma, and transplant rejection, significantly threaten human health worldwide. Polymer-based nanomedicines, which can be easily engineered with ideal physicochemical characteristics and functions, have considerable merits, including contributions to improved therapeutic outcomes and reduced adverse effects of drugs, in the treatment of hepatic diseases compared to traditional therapeutic agents. This review describes liver anatomy and function, and liver targeting strategies, hepatic disease treatment applications and intrahepatic fates of polymeric nanomedicines. The challenges and outlooks of hepatic disease treatment with polymeric nanomedicines are also discussed.
肝脏是人体的重要器官,具有多种功能,如消化、解毒、代谢、免疫反应以及储存维生素和矿物质。因此,由乙型肝炎病毒感染、非酒精性脂肪性肝炎、肝纤维化、肝细胞癌和移植排斥等各种肝脏疾病引起的肝功能障碍,严重威胁着全球人类的健康。与传统治疗剂相比,基于聚合物的纳米药物具有易于设计理想理化特性和功能的优点,在肝脏疾病的治疗中具有提高治疗效果和降低药物不良反应的优势。本文描述了肝脏解剖和功能,以及肝靶向策略、聚合物纳米药物在肝脏疾病治疗中的应用及其在肝脏内的命运。还讨论了聚合物纳米药物治疗肝脏疾病的挑战和展望。